Synthace
Synthace is a software company that powers life science the way it should be done. The company provides a life sciences R&D cloud to scientists who want to innovate faster. The Synthace platform seamlessly automates experimentation and insight sharing so that scientists can focus on asking the most impactful questions and unlocking the true potential of biology.
Sector
Industrial Biotech
Strategies
Crossover & Industrial Biotech
Status
Live
Website
www.synthace.com
Joško Bobanović
Partner, Sofinnova Partners - Industrial Biotech Strategy
Joe Anderson
Partner, Sofinnova Partners - Crossover Strategy
Related News
Synthace Raises $35M to Expand Access to Its Revolutionary R&D Technology for Life Changing Research
Synthace and Tecan Announce Collaboration to Accelerate Purification Optimization in Process Development through Augmented Lab Automation
Computer Aided Biology Pioneer Synthace Secures $25.6 Million in Series B Funding
Synthace Launches Ground-Breaking New Whitepaper: Computer-Aided Biology: Delivering Biotechnology in the 21st Century
Synthace Appoints Bob Wiederhold as Chairman of its Board of Directors
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.